Amerikanische Gesellschaft für Hirudotherapie

Alternative Non-Drug Treatment Options of the Most Neglected Parasitic Disease Cutaneous Leishmaniasis: A Narrative Review

Review published in Trop Med Infect Dis (2023)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewKlinische StudienSicherheit & InfektionskontrolleArzneimittelentwicklungOrabi MAA et al. · Tropical medicine and infectious disease, 2023

Abstract

With more than 12 million cases worldwide, leishmaniasis is one of the top 10 neglected tropical diseases. According to the WHO, there are approximately 2 million new cases each year in foci in around 90 countries, of which 1.5 million are cutaneous leishmaniasis (CL). Cutaneous leishmaniasis (CL) is a complex cutaneous condition that is caused by a variety of Leishmania species, including L. (Leishmania) major, L. (L) tropica, L. (L) aethiopica, L. (L) mexicana, L. (Viannia) braziliensis, and L. (L) amazonensis. The disease imposes a significant burden on those who are affected since it typically results in disfiguring scars and extreme social stigma. There are no vaccines or preventive treatments available, and chemotherapeutic medications, including antimonials, amphotericin B, miltefosine, paromomycin, pentamidine, and antifungal medications, have a high price tag, a significant risk of developing drug resistance, and a variety of systemic toxicities. To work around these limitations, researchers are continuously looking for brand-new medications and other forms of therapy. To avoid toxicity with systemic medication use, high cure rates have been observed using local therapy techniques such as cryotherapy, photodynamic therapy, and thermotherapy, in addition to some forms of traditional therapies, including leech and cauterization therapies. These CL therapeutic strategies are emphasized and assessed in this review to help with the process of locating the appropriate species-specific medicines with fewer side effects, lower costs, and elevated cure rates.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview

Zusammenfassung

Narrative review of non-drug treatments for cutaneous leishmaniasis including leech therapy alongside cryotherapy, photodynamic therapy, and thermotherapy. Discusses traditional therapies in the context of drug-resistant cutaneous leishmaniasis.

Warum dies für die Hirudotherapie relevant ist

This review assessed treatment options for cutaneous leishmaniasis, covering both systemic chemotherapeutic medications (antimonials, amphotericin B, miltefosine, paromomycin, pentamidine, antifungals) and local and traditional therapies including cryotherapy, photodynamic therapy, thermotherapy, leech therapy, and cauterization. The abstract states that high cure rates have been observed using local therapy techniques alongside traditional therapies including leech and cauterization therapies, presented as alternatives to avoid systemic toxicity. For ASH, the relevance is limited: leech therapy is listed as one traditional modality reportedly associated with high cure rates for CL, but no species-specific protocol, mechanism, safety, or outcome data are provided.

Zitation

Alternative Non-Drug Treatment Options of the Most Neglected Parasitic Disease Cutaneous Leishmaniasis: A Narrative Review.

Orabi MAA et al. · Tropical medicine and infectious disease, 2023

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.